B7x - From bench to bedside

Gurbakhash Kaur, Murali Janakiram

Research output: Contribution to journalArticle

Abstract

B7x is an immune checkpoint molecule which belongs to the B7 family of ligands which includes PD-L1, PD-L2, B7-H3 and HHLA2. B7x belongs to the Immunoglobulin superfamily and its protein structure is similar to other members with a N terminus peptide, IgV and IgC like extracellular domain with four cysteine residues. Its receptor is yet to be identified. B7x inhibits T cell proliferation and expansion by IL-2 dependent and non-IL-2 dependent pathways. Even though high levels of B7x mRNA can be detected in most tissues its protein expression is highly limited suggesting significant post translational control. In vivo data, show that B7x plays an important role in limiting autoimmunity in the peripheral tissues and fine-tuning autoimmune responses. B7x is highly expressed in various cancers and in prostate cancer its expression is corelated with poorer outcomes. Local production of IL-6 and IL-10 in various cancers promotes B7x expression and tumor immune evasion. B7x is especially expressed in PD-L1 negative tumors suggesting that this may be an important method of immune evasion in these tumors. Currently drug development, targeting B7x through various mechanisms including monoclonal antibodies and antibody drug conjugates are in development in cancers and increasing B7x expression with fusion proteins in autoimmune diseases is underway.

Original languageEnglish (US)
Article numbere000554
JournalESMO Open
Volume4
Issue number5
DOIs
StatePublished - Sep 1 2019

Fingerprint

Tumor Escape
Autoimmunity
Prostatic Neoplasms
Neoplasms
Proteins
Drug Delivery Systems
Interleukin-10
Autoimmune Diseases
Interleukin-2
Cysteine
Immunoglobulins
Interleukin-6
Monoclonal Antibodies
Cell Proliferation
Ligands
T-Lymphocytes
Messenger RNA
Peptides
Antibodies
Pharmaceutical Preparations

Keywords

  • B7 homolog 4
  • B7-H4
  • B7S1
  • B7x
  • immune checkpoint blockade
  • immunotherapy
  • novel immune checkpoints
  • VTCN1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

B7x - From bench to bedside. / Kaur, Gurbakhash; Janakiram, Murali.

In: ESMO Open, Vol. 4, No. 5, e000554, 01.09.2019.

Research output: Contribution to journalArticle

Kaur, Gurbakhash ; Janakiram, Murali. / B7x - From bench to bedside. In: ESMO Open. 2019 ; Vol. 4, No. 5.
@article{d91b746d82a8485babc243a404721550,
title = "B7x - From bench to bedside",
abstract = "B7x is an immune checkpoint molecule which belongs to the B7 family of ligands which includes PD-L1, PD-L2, B7-H3 and HHLA2. B7x belongs to the Immunoglobulin superfamily and its protein structure is similar to other members with a N terminus peptide, IgV and IgC like extracellular domain with four cysteine residues. Its receptor is yet to be identified. B7x inhibits T cell proliferation and expansion by IL-2 dependent and non-IL-2 dependent pathways. Even though high levels of B7x mRNA can be detected in most tissues its protein expression is highly limited suggesting significant post translational control. In vivo data, show that B7x plays an important role in limiting autoimmunity in the peripheral tissues and fine-tuning autoimmune responses. B7x is highly expressed in various cancers and in prostate cancer its expression is corelated with poorer outcomes. Local production of IL-6 and IL-10 in various cancers promotes B7x expression and tumor immune evasion. B7x is especially expressed in PD-L1 negative tumors suggesting that this may be an important method of immune evasion in these tumors. Currently drug development, targeting B7x through various mechanisms including monoclonal antibodies and antibody drug conjugates are in development in cancers and increasing B7x expression with fusion proteins in autoimmune diseases is underway.",
keywords = "B7 homolog 4, B7-H4, B7S1, B7x, immune checkpoint blockade, immunotherapy, novel immune checkpoints, VTCN1",
author = "Gurbakhash Kaur and Murali Janakiram",
year = "2019",
month = "9",
day = "1",
doi = "10.1136/esmoopen-2019-000554",
language = "English (US)",
volume = "4",
journal = "ESMO Open",
issn = "2059-7029",
publisher = "BMJ Publishing Group",
number = "5",

}

TY - JOUR

T1 - B7x - From bench to bedside

AU - Kaur, Gurbakhash

AU - Janakiram, Murali

PY - 2019/9/1

Y1 - 2019/9/1

N2 - B7x is an immune checkpoint molecule which belongs to the B7 family of ligands which includes PD-L1, PD-L2, B7-H3 and HHLA2. B7x belongs to the Immunoglobulin superfamily and its protein structure is similar to other members with a N terminus peptide, IgV and IgC like extracellular domain with four cysteine residues. Its receptor is yet to be identified. B7x inhibits T cell proliferation and expansion by IL-2 dependent and non-IL-2 dependent pathways. Even though high levels of B7x mRNA can be detected in most tissues its protein expression is highly limited suggesting significant post translational control. In vivo data, show that B7x plays an important role in limiting autoimmunity in the peripheral tissues and fine-tuning autoimmune responses. B7x is highly expressed in various cancers and in prostate cancer its expression is corelated with poorer outcomes. Local production of IL-6 and IL-10 in various cancers promotes B7x expression and tumor immune evasion. B7x is especially expressed in PD-L1 negative tumors suggesting that this may be an important method of immune evasion in these tumors. Currently drug development, targeting B7x through various mechanisms including monoclonal antibodies and antibody drug conjugates are in development in cancers and increasing B7x expression with fusion proteins in autoimmune diseases is underway.

AB - B7x is an immune checkpoint molecule which belongs to the B7 family of ligands which includes PD-L1, PD-L2, B7-H3 and HHLA2. B7x belongs to the Immunoglobulin superfamily and its protein structure is similar to other members with a N terminus peptide, IgV and IgC like extracellular domain with four cysteine residues. Its receptor is yet to be identified. B7x inhibits T cell proliferation and expansion by IL-2 dependent and non-IL-2 dependent pathways. Even though high levels of B7x mRNA can be detected in most tissues its protein expression is highly limited suggesting significant post translational control. In vivo data, show that B7x plays an important role in limiting autoimmunity in the peripheral tissues and fine-tuning autoimmune responses. B7x is highly expressed in various cancers and in prostate cancer its expression is corelated with poorer outcomes. Local production of IL-6 and IL-10 in various cancers promotes B7x expression and tumor immune evasion. B7x is especially expressed in PD-L1 negative tumors suggesting that this may be an important method of immune evasion in these tumors. Currently drug development, targeting B7x through various mechanisms including monoclonal antibodies and antibody drug conjugates are in development in cancers and increasing B7x expression with fusion proteins in autoimmune diseases is underway.

KW - B7 homolog 4

KW - B7-H4

KW - B7S1

KW - B7x

KW - immune checkpoint blockade

KW - immunotherapy

KW - novel immune checkpoints

KW - VTCN1

UR - http://www.scopus.com/inward/record.url?scp=85072210151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072210151&partnerID=8YFLogxK

U2 - 10.1136/esmoopen-2019-000554

DO - 10.1136/esmoopen-2019-000554

M3 - Article

VL - 4

JO - ESMO Open

JF - ESMO Open

SN - 2059-7029

IS - 5

M1 - e000554

ER -